行情

CELGZ

CELGZ

Celgene
NASDAQ

实时行情|Nasdaq Last Sale

0.4400
-0.0402
-8.37%
休市 16:00 11/15 EST
开盘
0.5099
昨收
0.4802
最高
0.5100
最低
0.4350
成交量
18.39万
成交额
--
52周最高
1.650
52周最低
0.3500
市值
3.13亿
市盈率(TTM)
0.0549
分时
5日
1月
3月
1年
5年

CELGZ 新闻

  • 花旗策略师:美股明年面临四大障碍
  • 新浪美股.4小时前
  • 三大指数提供商最快在12月将沙特阿美纳入其指数
  • 新浪美股.6小时前
  • 日韩企业联手 韩媒:将对阿里腾讯构成巨大威胁
  • 参考消息.8小时前
  • 外媒:流媒体平台如何改变人们看电视的方式
  • 参考消息.8小时前

更多

所属板块

制药
+1.37%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

CELGZ 简况

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
展开

Webull提供Celgene Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。